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ABSTRACT
Introduction: Chronic venous disease (CVD) of
the lower limbs is a common problem. It is
more prevalent in women than in men and has
a significant impact on patients’ quality of life
(QoL) and on the healthcare system. The aim of
this study was to evaluate the efficacy of
sulodexide in adult patients with CVD of the
lower limbs and its effect on patients’ QoL.
Methods: Patients with CVD were treated with
sulodexide [250 LSU (lipasemic units) twice
daily] for 3 months in a setting of real-life
clinical practice. The endpoints of this
observational non-comparative, open-label
prospective study were the clinical efficacy of
sulodexide (evaluated by scoring objective and
subjective symptoms with a Likert-type scale)
and the impact of sulodexide therapy on
patients’ QoL [assessed using the chronic
venous insufficiency quality of life
questionnaire (CIVIQ)].
Results: The study included 450 patients (mean
age 46.9 ± 10.5 years, range 17–78 years). A
greater percentage of patients were female
(65.4%). Three months of treatment with
sulodexide significantly improved all objective
and subjective symptoms (p\0.0001). Overall,
patients reported a significant improvement in
all QoL scores (p\0.0001). Adverse events were
spontaneously reported by two patients (one
case of epigastric pain and one of gastric pain
with vomiting).
Conclusion: Oral sulodexide significantly
improves both objective and subjective
symptoms, as well as functional and
psychological aspects of QoL in patients with
CVD.
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processing charges and open access fees was
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INTRODUCTION
Chronic venous disease (CVD) of the lower
limbs is a condition of the venous system in
which venous hypertension may cause various
symptoms and signs that may include (in the
order of severity, greatest to least): pain,
swelling, oedema, skin changes, subcutaneous
tissue fibrosis and ulcerations [1]. In CVD,
normal venous pressure is increased and the
return of blood is impaired via several
mechanisms, such as structural or functional
alteration of the vein walls, valvular
incompetence of deep, superficial or perforator
veins, venous obstruction or a combination of
these [1]. Occurring more frequently in women
than in men, CVD is a common medical
condition that has a significant impact on
patients’ quality of life (QoL) and the
healthcare system [1, 2].
Inflammatory processes have demonstrated
involvement in structural remodelling of
venous valves and the vein wall, leading to
valvular incompetence and the development of
varicose veins [3]. Various factors can lead to
inflammation of the vessel wall. The venous
system of the lower limbs undergoes frequent
postural pressure changes; however, prolonged
periods of sitting or standing can lead to
venous stasis, which causes vein distension
and valve distortion. Leakage of blood through
these damaged valves leads to flow reversal,
which in turn initiates endothelial and
leukocyte activation [4]. These inflammatory
stresses, when repeated over time, eventually
lead to chronic recurrent injury to the venous
wall, perpetuating inflammation at the vein
level [4].
A second significant pro-inflammatory factor
is altered shear stress. Normal shear stress, or
steady laminar blood flow, promotes the release
of factors that reduce inflammation and the
formation of reactive free radicals [1]. In
contrast, low or zero shear stress (disturbed or
turbulent flow and especially reversal of the
direction of blood flow) induces venous
inflammation and thrombosis [1]. The
endothelium, particularly the endothelial
glycocalyx (the carbohydrate-rich layer of
proteoglycans and glycoprotein lining the
vascular endothelium) [5], is responsible for
translating biomechanical forces into protective
biochemical signals (e.g. the production of the
vasodilator nitric oxide) [1, 5]. Almost all of the
mechanical stress caused by luminal flow is
transferred to the glycocalyx, thus virtually
eliminating the shear stress at the surface of
the venular endothelium [1]. The glycocalyx
also inhibits leukocyte adhesion by masking cell
adhesion molecules [1]. However, the
glycocalyx may be damaged by inflammation
which may alter responses to shear stress and
result in further leukocyte adhesion.
Irrespective of the trigger for inflammatory
events in venous valves and walls, various
inflammatory mediators and growth factors are
released. These include chemokines, cytokines,
matrixmetalloproteinases, vascular cell adhesion
molecule-1, intercellular adhesion molecule-1,
transforming growth factor beta, fibroblast
growth factor beta and vascular endothelial
growth factor [4, 6]. Together, these
inflammatory mediators and growth factors
perpetuate inflammation, leading to structural
remodelling of vein walls and valves, venous
dilation, varicose veins and ulceration [6].
Early treatment for the prevention of
venous hypertension and the inhibition
of the inflammatory cascade, especially
leukocyte-endothelium interactions, could
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alleviate symptoms of CVD and slow or prevent
disease progression to chronic venous
insufficiency (CVI) and ulcers [1, 3]. The current
recommended first-line treatment of CVD
involves conservative measures, such as lifestyle
modifications and compression therapy, with
frequent addition of veno-active drugs for the
treatment of CVD-related symptoms [4, 7].
Interventional therapy is only considered for the
treatment of specific signs and symptoms or if
conservative therapy fails [7].
Sulodexide is a specific glycosaminoglycan
(GAG), composed of a fast-moving heparin
fraction (80%) with affinity for antithrombin III,
and a dermatan sulphate fraction (20%) with
affinity for heparin cofactor II [8]. Sulodexide
exerts a strong anti-thrombotic activity by
simultaneously potentiating the antiprotease
activities of both antithrombin III and heparin
cofactor II [8]. Sulodexide also has a profibrinolytic
effect (via activation of tissue plasminogen
activator and inhibition of plasminogen activator
inhibitor), an antiproliferative effect on smooth
muscle cells and antilipaemic and
antiatherosclerotic effects [8].
Several clinical studies have demonstrated
the efficacy of sulodexide in the treatment or
prevention of vascular diseases associated with
increased thrombotic risk, such as peripheral
arterial occlusive diseases [9, 10],
post-myocardial infarction [11], recurrent deep
vein thrombosis [12, 13] and post-thrombotic
syndrome [14, 15].
More recently, the antiplatelet [16] and
anti-inflammatory [17] activities of sulodexide
have been highlighted, together with its
significant protective effect on the glycocalyx
layer [18]. This suggests that the administration
of sulodexide in patients with CVD may
interfere with the pathogenesis of the disease,
not only when it is linked to previous deep vein
thrombosis (secondary venous disease or
post-thrombotic syndrome), but also in case of
primary venous disease. In fact, favourable
effects on clinical signs and symptoms of CVD
have been documented following the
administration of sulodexide regardless of the
underlying aetiology of the venous disease
[19, 20]. However, no data are currently
available in peer review publications regarding
the effects of sulodexide on patients’ QoL using
validated tests.
The aim of this study was to evaluate the
effect of oral sulodexide on both clinical
symptoms and QoL in adult patients with
CVD of the lower limbs.
METHODS
This observational non-comparative, open-label
prospective study was conducted at 50 centres in
Tunisia during 2008 (see the complete list at the
endof thearticle).Adult patientswithCVDof the
lower limbs were included. Exclusion criteria
included: age [70 years; presence of
arteriopathies of the lower limbs; rheumatic,
musculotendinous, neurologic, metabolic or
haemorrhagic diseases, including haemorrhagic
diathesis; concomitant anticoagulant treatment;
hypersensitivity to sulodexide or other GAGs.
Pregnant or breastfeeding women were also
excluded.
Patients were evaluated at baseline
(enrolment visit, T0) and after 3 months (end
of study visit, T3) of oral treatment with
sulodexide capsules (Vessel, Alfa
Wassermann, Alanno (PE), Italy) 250 LSU
(lipasemic units, approximately equivalent to
25 mg) twice daily. Demographic data (sex, age,
origin area) were collected during the
enrolment visit. At both visits, the investigator
evaluated subjective symptoms (heaviness,
pain, cramps and paresthesias) and objective
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symptoms (erythema, skin temperature and
induration) of CVD in the lower limbs using a
4-point Likert-type scale (0-absent, 1-moderate,
2-severe and 3-very severe).
In addition, the chronic venous
insufficiency quality of life (CIVIQ)
questionnaire was used to gauge patients’
QoL based on self-evaluation of their health
status over the last 4 weeks using a 5-point
Likert-type scale (1-best possible condition,
5-worst possible condition). This
questionnaire was developed by Prof. Launois
with an educational grant from Servier
[21, 22]. Assessments were performed at
baseline and after 3 months of therapy with
sulodexide and included the patient’s
assessment of severity of pain, functional
limitation (in general and in individual
activities), sleep and several psychological
aspects related to CVD.
The endpoints of the study were the clinical
effectiveness of sulodexide treatment and its
impact on patients’ QoL. Tolerability of
sulodexide was not formally analysed as
patients were not systematically asked about
the occurrence of adverse events during the
study period, nor at the final visit.
All procedures followed were in accordance
with the Helsinki Declaration of 1964, as revised
in 2013. Informed consent was obtained from
all patients for being included in the study.
Statistical Analysis
Data were summarised using standard
descriptive methods. Symptom and QoL scores
were analysed at both T0 and T3, when
available. Mean compound scores were
calculated for all symptoms [functional QoL
(including pain-related symptoms), and mental
QoL (including sleep-related symptoms)],
providing that more than half of the
questionnaire items were answered at both T0
and T3. Comparisons between visits were
carried out using Wilcoxon’s test for paired
samples (signed rank test). Two-sided p\0.01
were considered as statistically significant. T3/
T0 mean compound score ratios were analysed
using mixed models, with age (B45 or
[45 years) and gender as fixed effects, and
centre as random effect. Statistical analysis was
carried out using the SAS System version 8.2.
RESULTS
Patients
A total of 450 patients were included in the
study, mostly from urban (92.9%) rather
than rural (7.1%) areas. The mean age (±SD)
of patients was 46.9 ± 10.5 years (range
17–78 years); 53.0% were[45 years and three
patients were[70 years (older than the upper
limit of 70 years specified for the study). A
higher proportion of patients were females
(65.4%). A total of 436 patients (96.9%)
completed the study by attending the final
visit at 3 months after enrolment. Reasons for
failing to complete the study included
withdrawal from the study because of
adverse events (specifically, epigastric pain
and gastric pain with vomiting; 2 patients)




The number and percentage of patients with
each score for subjective and objective
symptoms at both T0 and T3 are reported in
Table 1. The number of patients with data
available from both visits varied from 430
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patients for leg heaviness to 410 patients for
erythema.
Three months of treatment with sulodexide
significantly improved all subjective and
objective symptoms: the median improvement
for all symptoms was 1 unit on the Likert scale,
meaning median values shifted from severe to
moderate for leg heaviness and pain and from
moderate to absent for all other symptoms.Mean
symptom scores at baseline and at the final visit
are shown in Fig. 1. All improvements were
statistically significant (p\0.0001). Mean
compound scores at T0 and T3 and their percent
reduction at T3 compared with T0, calculated for
each patient, are summarised in Table 2. All
changes were statistically significant (p\0.0001)
in each of the four subgroups, in which patients
were stratifiedby age and gender.Centre-adjusted
differences between age and gender subgroups in
T3/T0 score ratioswerenot statistically significant
(p[0.05).
Patients attending for observation in our
centres presented mostly with subjective
symptoms of severe or very severe intensity
(heaviness, 54.9% and 31.6%, respectively;
pain, 48.8% and 29.0%, respectively) or of
severe to moderate intensity (cramps, 36.0%
and 36.0%, respectively; paresthesias, 33.3%
and 33.3%, respectively). Up to slightly more
than one-third of patients showed no objective
symptoms (erythema, 36.6%; skin temperature,
25.5%; induration, 37.1%) at baseline; when
present, these symptoms were mostly reported
as moderate or severe (Table 1). Treatment with
sulodexide reduced the intensity of each
subjective and objective symptom, an effect
Table 1 Lower limb objective and subjective symptoms (N%) at baseline (T0) and ﬁnal visit (T3) according to severity
(Likert-type scale) (p\0.0001 for all differences between T0 and T3)
Symptom Visit Total Absent Moderate Severe Very severe
N n (%) n (%) n (%) n (%)
Heaviness T0 430 11 (2.6) 47 (10.9) 236 (54.9) 136 (31.6)
T3 430 128 (29.8) 241 (56.0) 56 (13.0) 5 (1.2)
Pain T0 424 13 (3.1) 81 (19.1) 207 (48.8) 123 (29.0)
T3 424 162 (38.2) 205 (48.3) 54 (12.7) 3 (0.7)
Cramps T0 425 76 (17.9) 153 (36.0) 153 (36.0) 43 (10.1)
T3 425 256 (60.2) 139 (32.7) 29 (6.8) 1 (0.2)
Paresthesias T0 421 98 (23.3) 140 (33.3) 140 (33.3) 43 (10.2)
T3 421 243 (57.7) 141 (33.5) 36 (8.6) 1 (0.2)
Erythema T0 410 150 (36.6) 117 (28.5) 119 (29.0) 24 (5.9)
T3 410 267 (65.1) 117 (28.5) 26 (6.3) 0 (0.0)
Skin temperature T0 416 106 (25.5) 153 (36.8) 124 (29.8) 33 (7.9)
T3 416 258 (62.0) 145 (34.9) 13 (3.1) 0 (0.0)
Induration T0 418 155 (37.1) 115 (27.5) 112 (26.8) 36 (8.6)
T3 418 256 (61.2) 143 (34.2) 18 (4.3) 1 (0.2)
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which was directly proportional to its initial
intensity (Fig. 1).
Quality of Life
All the items of the CIVIQ questionnaire were
evaluated at T0 and T3. The number of patients
with data available from both visits varied across
the items, from 426 patients for ‘‘Climbing stairs’’
(F2) to 404patients for ‘‘Sporting activities,making
physically strenuous efforts’’ (F8). After 3 months
of treatment, the median improvement for all
itemswas 1unit on theLikert-type scale, except for
the item ‘‘Standing for a long time’’ (F1), which
showed a median improvement of 2 units. Mean
scores at T0 and T3 are shown in Figs. 2 and 3; all
improvementswerehighly significant (p\0.0001)
and similar for questions related to pain and
functional activities (mean improvement of 44%)
and to sleep and mental symptoms (mean
improvement of 40%) (Table 2). Changes were
statistically significant in each of the four
subgroups, in which patients were stratified by
age and gender (p\0.0001). No statistically
significant differences were observed between the
subgroups (p[0.05).
Safety
Adverse events were spontaneously reported by
two patients (epigastric pain and gastric pain
with vomiting). However, other patients were
not systematically asked about adverse events so
no other data are available.
DISCUSSION
In our study, administration of oral sulodexide
for 3 months to 450 adult patients with CVD in
a setting of real-life clinical practice led to
statistically significant improvements in the
subjective (heaviness, pain, cramps and
paresthesias) and objective (erythema, skin
temperature and induration) symptoms as well







































Fig. 1 Lower limb objective and subjective symptoms mean severity score at baseline and after 3 months of treatment with
sulodexide
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These results are consistent with those of
previous studies reporting the effectiveness of
sulodexide in the treatment of CVD. A
double-blind, double-dummy, randomised
study by Saviano and co-workers [19]
compared the efficacy, dose–effect relationship
and tolerability of sulodexide given orally as
capsules or enteric coated tablets for 60
consecutive days in 476 patients with CVI.
The results of the study showed a dose-related
and statistically significant decrease in the
number and intensity of the subjective and
objective symptoms such as pain, limb
heaviness, paresthesias, nocturnal cramps, foot
and leg oedema, skin pigmentation,
hypodermitis, lymphangitis and stasis ulcer
with sulodexide treatment. With the exception
of hypodermitis, lymphangitis and stasis ulcer,
which were present in a small number of
patients and with a limited intensity at
baseline, the reduction in the intensity of
symptoms compared with baseline was first
observed at 30 days (p\0.025) in all dose
groups. Another randomised, double blind,
multicentre, placebo controlled study
evaluated the effect of sulodexide in the
treatment of venous leg ulcers ([2 cm in
diameter), with complete healing of ulcers at
Table 2 Mean compound scores at baseline (T0) and at ﬁnal (T3) visit and their ratio in the overall patient population and
in subgroups by gender and age (p\0.0001 for all differences between T0 and T3)
Compound score All patients Female Female Male Male
£45 years >45 years £45 years >45 years
Symptoms (s)
N 428 115 137 65 75
T0 mean 1.46 1.35 1.53 1.37 1.52
T3 mean 0.55 0.49 0.56 0.67 0.53
T3/T0 mean (%) 33 35 37 45 34
Functional quality of life (f)
N 428 116 137 66 74
T0 mean 3.02 3.04 3.15 2.73 3.04
T3 mean 1.71 1.76 1.77 1.53 1.76
T3/T0 mean (%) 56 59 57 58 59
Mental quality of life (m)
N 423 117 135 65 73
T0 mean 2.61 2.61 2.79 2.31 2.48
T3 mean 1.56 1.55 1.63 1.39 1.53
T3/T0 mean (%) 60 62 61 64 65
Lower scores represent better conditions
(s) heaviness, pain, cramps, paresthesias, erythema, skin temperature, induration
(f) pain-related, functional general and functional speciﬁc 1–8 (details in Fig. 2)
(m) sleep-related and mental 1–9 (details in Fig. 3)
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2 months as the primary endpoint [20]. Venous
leg ulcers are the most severe manifestation of
CVD and the healing of a venous ulcer
represents an important, objective and ‘hard’
endpoint in defining the role of medications for
the treatment of CVD. The trial involved a total
of 230 patients, randomised to sulodexide
(n = 120) or placebo (n = 110) in addition to
local treatment, including wound care and
compression bandaging. In the intent-to-treat
population the primary endpoint was reached
in 35.0% of patients receiving sulodexide and
20.9% of placebo recipients (p = 0.018). At
3 months the difference between the
sulodexide and placebo groups increased
further, with healing rates of 52.5% in patients
receiving sulodexide and 32.7% in those
receiving placebo (p = 0.004). The reduction in
ulcer surface area with time was significant for
the sulodexide group (p = 0.004) and the
treatment was well tolerated, with no
differences in adverse events reported between
the sulodexide and placebo group.
QoL reflects the patients’ perception of their
‘‘well-being’’ at any time and, therefore, it is an
important health outcome. Illness has a
profound effect on a patient’s QoL and
questionnaires, both generic and specific for
venous disease, show that QoL is adversely














P = Pain-related: in the past four weeks, if you have felt pain in the ankles or legs, what was the intensity of this pain?
Fg = Functional general: during the past four weeks, to what extent did you feel bothered/limited in your work or your other daily 
 activities because of your leg problems?
F1-F8 = Functional specific: during the past four weeks, to what extent your leg problems bothered/limited you while doing the 
 movements or activities listed below?
 F1 = Standing for a long time
 F2 = Climbing stairs
 F3 = Crouching, kneeling
 F4 = Walking briskly
 F5 = Travel by car, bus, plane
 F6 =  Housework such as working in the kitchen, carrying a child, ironing, cleaning floors or furniture, doing hard work
 F7 = Going to discos, weddings, parties, cocktails
































Fig. 2 Quality of life (pain-related and functional
activities) in patients receiving sulodexide for chronic
venous disease. Mean chronic venous insufﬁciency quality
of life (CIVIQ) questionnaire scores as assessed by patients
at baseline and after 3 months of treatment with sulodexide.
Lower scores in the CIVIQ mean better quality of life
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reduction in the severity of disease, for example
after treatment, is reflected in the QoL [7]. Our
data show that 3 months of treatment with
sulodexide significantly improved the QoL of
patients with CVD in pain-related and
functional items as well as in sleep and mental
items.
Since our study is the first evaluating the
effects of sulodexide in CVD patients using a
validated questionnaire for the measurement of
QoL, comparisons can only be made with
studies carried out with other phlebotropic
drugs. In a large prospective international,
multicentre study, that was non-comparative
as far as treatment is concerned, QoL was
evaluated using the CIVIQ questionnaire in
more than 3600 patients with CVI. Treatment
with 1000 mg of micronized purified flavonoid
fraction administered daily for 6 months
resulted in a significant improvement of QoL,
which was greater after 2 months of treatment,












S = Sleep-related: during the past four weeks, did you sleep badly because of your legs problems, and how often?
M1-M9 = Mental: leg problems can also have an effect on one’s morale. To what extent do the following sentences 
  correspond to the way you have felt during the past four weeks?
 M1 = I feel on edge
 M2 = I become tired quickly
 M3 = I feel I am a burden to people
 M4 = I must always take precautions (such as to stretch my legs, to avoid standing for a long time…)
 M5 = I am embarrassed to show my legs
 M6 = I get irritated easily 
 M7 = I feel handicapped
 M8 = I have difficulty getting going in the morning
































Fig. 3 Quality of life (sleep-related and mental symptoms)
in patients receiving sulodexide for chronic venous disease.
Mean chronic venous insufﬁciency quality of life (CIVIQ)
questionnaire scores as assessed by patients at baseline and
after 3 months of treatment with sulodexide. Lower scores
in the CIVIQ mean better quality of life
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6 months [23]. Among other large trials using
the CIVIQ questionnaire as a quantitative
instrument to assess health-related QoL
changes in patients with CVD, a very
short-term (7 days) study by Guex and
colleagues reported statistically significant
improvements in QoL in 399 symptomatic
female patients treated with an unspecified
phlebotropic drug [24]. More recently, an
observational, single arm, international,
multicentre, prospective trial in 1953 patients
with CVD showed that the administration of a
combination of Ruscus aculeatus (150 mg),
hesperin methyl chalcone (150 mg) and
ascorbic acid (100 mg) twice daily resulted in
significant improvements in QoL after 12 weeks
of treatment [25].
To our knowledge, only a few
placebo-controlled studies have evaluated the
effects of treatment with veno-active drugs on
the QoL of patients with CVD. In a recent trial,
Belczak and colleagues [26] studied the effects of
different veno-active drugs on limb volume
reduction, tibiotarsal range of motion, and QoL
in 136 patients with CVD; a 30-day treatment
withdiosminplushesperidin (450 and50 mg), or
aminaphtone (75 mg), or coumarin plus
troxerutin (15 and 90 mg) or placebo every 12 h
showed a significant improvement in QoL
(a) versus baseline in the aminaphtone and
diosmin plus hesperidin treatment groups and
(b) versus placebo only in the aminaphtone
group (p = 0.007), while in the diosmin plus
hesperidine group the improvement tended
toward significance (p = 0.055). Another
randomised, double-blind, placebo-controlled
trial including 509 patients with CVD suggested
that the effects of calciumdobesilate onQoLmay
bedependenton thedurationof treatment: there
was no significant difference in QoL, measured
by the CIVIQ questionnaire, between calcium
dobesilate (500 mg twice a day) and placebo
(p = 0.07) at 3 months (the primary endpoint),
but a significant difference in favour of calcium
dobesilate (p = 0.02) was observed after
12 months of treatment (a secondary endpoint)
[21].
In our study, treatment with sulodexide
showed significant improvement from baseline
of both QoL and clinical symptoms after
3 months of treatment in an adequate number
of patients. However, no control group was
used, which is a significant limitation of the
study, and caution should be exercised in the
evaluation of the results as improvements may
be in part due to a greater care to which the
patients included in clinical trials are subjected.
Nevertheless, it should be noted that the
changes in symptoms and signs reported in
similar randomised, controlled studies moved
in the same favourable direction. In our study
the response to sulodexide treatment was
assessed by evaluating some important
subjective and objective symptoms of CVD
using the 4-point Likert-type scale. However,
no widely accepted classification of CVD, such
as the CEAP classification [27], was referred to,
which is another limitation of the study. Also,
the lack of a systematic active collection of
tolerability data was a clear limitation of the
study. Treatment emergent adverse events were
only recorded if spontaneously reported by the
study patients. However, the clinical experience
with sulodexide in patients with CVD shows
that the drug is generally well tolerated
[14, 15, 19, 20, 28–35].
CONCLUSIONS
In spite of the limitations, our data on more
than 400 patients provide additional support
for the use of sulodexide in patients with CVD.
In particular, after 3 months of treatment with
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sulodexide, we documented a significant
increase in QoL in comparison with the
pre-treatment conditions, and observed
significant improvement in clinical signs and
symptoms as already shown in previous
randomised controlled studies in patients with
CVD. Improvement of signs, symptoms and
QoL was similar irrespective of age and gender.
Sulodexide is already included among the few
drugs recommended for the treatment of this
indication in authoritative guidelines; however,
further randomised controlled studies in
specific patient populations would be
welcomed to better define its therapeutic role.
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